Skip to main content
HBB $33.34 +0.27%
HBB logo

HBB · Hamilton Beach Brands Holding Co

Track HBB — free
$33.34 +0.09 (+0.27%) At close · Aug 14
Market Cap
$448.17M
Shares
13.44M
All earnings calls

Earnings call · FY2026 Q1

Hamilton Beach Brands Holding Co Q1 FY2026 Earnings Call

Hamilton Beach Brands Holding Co Q1 FY2026 Earnings Call

Concluded May 6, 2026 Audio replay
May 6, 2026 19:25 11 turns
Period
FY2026 Q1
Runtime
19:25
Sources
4 artifacts

Executive readout · one minute

What matters this quarter

Hamilton Beach Brands reported Q1 2026 revenue down 8.6% to $122.0 million on weaker U.S. consumer demand, but gross margin expanded 510 basis points to 29.7% and operating profit grew 115% to $5.0 million as the company benefited from the Supreme Court's IEEPA tariff ruling and pricing actions. The company reiterated its 2026 guidance, including expected low-teens percentage decline in reported operating profit.

Gross margin expansion and tariff mitigation 15 Premium market share via LOTUS brand 14 2026 financial guidance 9 Hamilton Beach Health expansion 7 Core consumer product innovation 5 Digital transformation and marketing 5

Management tone

Positive

Net tone +28 · moderate hedging

Grounding quotes
  • “First quarter revenue was expected to be down year-over-year as we are up against a challenging comparison, and while it declined slightly more than planned, we delivered exceptional gross margin expansion of 510 basis points, which drove operating profit growth of 115% to $5 million.”
  • “Sales were modestly below our expectations, primarily because March was softer than planned. Consumers remained under pressure and discretionary spending weakened in parts of our business.”
  • “Our current earnings and cash flow outlook excludes any potential impact from IEPA-related refunds, which total approximately $41 million of tariffs paid in 2025 and early 2026 that the company is actively pursuing; however, the timing and ultimate recovery remain uncertain.”
  • “We are reiterating our previously issued guidance.”

Forward guidance

1 guided metrics

Management's latest ranges and targets are included below.

Research coverage

4 live sources

Switch sources without leaving this page or losing your listening position.

Revenue $121.96M -8.6% YoY
Diluted EPS $0.26 +100% YoY
Gross margin 29.7% +5.1 pp YoY
Net income $3.54M +96.1% YoY

Research materials

Open the source you need; every reader stays inside this workspace.

Key takeaways

What improved, and what deserves a closer read.

Constructive signals

  • Gross margin expanded 510 basis points to 29.7% from 24.6%, including a 190 bps one-time benefit from sell-through of inventory priced for IEEPA tariffs eliminated by the Supreme Court ruling.
  • Operating profit grew 115% to $5.0 million from $2.3 million, with diluted EPS rising to $0.26 from $0.13.
  • LOTUS Professional is rolling out to additional retailers after exclusivity ended in 2026, with LOTUS Signature launching in the fall and committed expanded shelf space from a key retail partner.
  • Health business is on track for 50% sales growth this year, marking its third consecutive quarter of profitable growth, with a new injectable drug on the SmartSharp Spin platform and a Q3 pill management platform pilot.
  • New commercial wins include the Eclipse blender being added to a leading national coffee chain and a new spindle maker placement for a leading U.S.-based fast food chain's Central America locations.
  • New shelf placements secured with a leading department store, two top wholesale membership clubs, and a leading mass market retailer.

Risks & pressure points

  • Revenue declined 8.6% to $122.0 million from $133.4 million due to softer March demand and weakened discretionary spending, particularly in the U.S. consumer business where elevated fuel costs pressured shoppers.
  • 2026 reported operating profit is still expected to decline low-teens on a percentage basis, inclusive of an incremental $6 million in planned advertising spend and approximately $6 million in accelerated legacy ERP depreciation.
  • The 190 bps IEEPA-related margin benefit is non-recurring and will not persist beyond the sell-through of affected inventory.
  • Recovery of approximately $41 million in IEEPA-related tariffs paid in 2025 and early 2026 remains uncertain and is excluded from guidance.
  • Operating cash flow declined to $3.3 million from $6.6 million, driven by higher net working capital after exiting a receivable sale arrangement.
  • Net debt rose to $2.6 million at quarter-end compared to $1.7 million a year earlier.

Key moments

Jump directly to management's words in the synchronized transcript.

“Our current earnings and cash flow outlook excludes any potential impact from IEPA-related refunds, which total approximately $41 million of tariffs paid in 2025 and early 2026 that the company is actively pursuing; however, the timing and ultimate recovery remain uncertain.” Sally Cunningham, CFO

Forward guidance

From the 8-K filed May 6, 2026.

Metric Guided
Cash flow from operating activities less cash used for investing
2026
$35M – $45M

Quarter detail

How the reported period landed and where the business moved.

Revenue · segments

Home and Commercial Products Segment$119.61M -9.3% YoY
Health Segment$2.35M +52.3% YoY

Capital returned

Buybacks
$1.21M
Shares repurchased
68,988
Dividend / share
$0.13
Full-screen source Call document